Drug Search Results
More Filters [+]

BTA-9881

Alternative Names: bta-9881, bta9881, bta 9881, medi-564, medi 564, medi564
Latest Update: 2018-05-30
Latest Update Note: Clinical Trial Update

Product Description

respiratory syncytial virus (RSV) fusion inhibitor

Mechanisms of Action: FP Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Vaxart
Company Location: SOUTH SAN FRANCISCO CA 94080
Company CEO: Andrei Floroiu
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for BTA-9881

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Respiratory Syncytial Virus Infections

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

BTA9881-01

P1

Completed

Respiratory Syncytial Virus Infections

2008-12-01

Recent News Events

Date

Type

Title